November 9, 2022
|
November 9, 2022
SINGAPORE – November 9, 2022 – Lion TCR announced the abstract of a Phase I clinical trial for primary hepatitis B virus (HBV)-related hepatocellular carcinoma (NCT03899415) has been reported at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022 as a poster presentation.
Title: Analysis of Biochemical and Immunological Alterations in Disease Control Group VS Disease Progression Group after Hepatitis B virus (HBV)-specific T-cell receptor (TCR) T cell therapy for Primary HBV-related Hepatocellular Carcinoma
Abstract No: 5056
Study Principal Investigator & Corresponding Author: Wang Fu Sheng
First Author: Meng Fan Ping
Patients with clinical response showed larger degree of reversible localized liver inflammation and larger anti-viral response, suggesting the on-target effects of LioCyx-M.
Importantly, patients with clinical response displayed activation of proliferative T-cell compartment and/or elevations of serum inflammatory chemokines, CXCL9 and CXCL10. These biomarker changes are suggestive of the activation of secondary immune responses resulting in a durable efficacy of these functionally short-lived HBV-specific TCR-T cells, which could explain the longer OS in this group of patients.
In contrast, non-responders did not display any detectable peripheral blood immunological alterations.
The data conclusively demonstrated the differential liver function, viral and immune alterations in patient with and without clinical response, implicating the importance of secondary immune response activation via the cancer-immunity cycle for durable anti-tumor effects of LioCyx-M.
This data highlights the promising use of HBV-specific TCR-T therapy in HBV-related HCC, and the same technology could potentially be extended to the treatment of other solid tumors in future.
About Lion TCR
Lion TCR is a Singapore based clinical-stage biotechnology company, focused on the development of T cell receptor (TCR)-T cell therapy against life-threatening viral infections and viral-related cancers.
About LioCyx-M
LioCyx-M, including several well-established product derivatives, are autologous T cells modified to express HBV-specific TCR. These modified T cells have been shown to be able to lyse HBV-infected HCC cells upon target recognition in various in vivo pre-clinical studies and in patients.
